Build-A-Bear Workshop Raises Annual Guidance

Build-A-Bear Workshop, Inc. (BBW) said, reflecting its positive business performance through the first nine months of the year, continued positive fourth quarter trends and expectation of continued strength during the period, it is raising annual guidance. Pre-tax income is projected in the range of $56 million to $63 million. Total revenues are expected in the range of $455 million to $465 million.

Third quarter earnings came in at $7.46 million, or $0.51 per share compared with $5.92 million, or $0.36 per share, a year ago. Revenue rose 9.8% to $104.48 million from $95.14 million last year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT